Skip to Content
Merck
  • Estradiol modulates translocator protein (TSPO) and steroid acute regulatory protein (StAR) via protein kinase A (PKA) signaling in hypothalamic astrocytes.

Estradiol modulates translocator protein (TSPO) and steroid acute regulatory protein (StAR) via protein kinase A (PKA) signaling in hypothalamic astrocytes.

Endocrinology (2014-06-01)
Claire Chen, John Kuo, Angela Wong, Paul Micevych
ABSTRACT

The ability of the central nervous system to synthesize steroid hormones has wide-ranging implications for physiology and pathology. Among the proposed roles of neurosteroids is the regulation of the LH surge. This involvement in the estrogen-positive feedback demonstrates the integration of peripheral steroids with neurosteroids. Within the female hypothalamus, estradiol from developing follicles stimulates progesterone synthesis in astrocytes, which activate neural circuits regulating gonadotropin (GnRH) neurons. Estradiol acts at membrane estrogen receptor-α to activate cellular signaling that results in the release of inositol trisphosphate-sensitive calcium stores that are sufficient to induce neuroprogesterone synthesis. The purpose of the present studies was to characterize the estradiol-induced signaling leading to activation of steroid acute regulatory protein (StAR) and transporter protein (TSPO), which mediate the rate-limiting step in steroidogenesis, ie, the transport of cholesterol into the mitochondrion. Treatment of primary cultures of adult female rat hypothalamic astrocytes with estradiol induced a cascade of phosphorylation that resulted in the activation of a calcium-dependent adenylyl cyclase, AC1, elevation of cAMP, and activation of both StAR and TSPO. Blocking protein kinase A activation with H-89 abrogated the estradiol-induced neuroprogesterone synthesis. Thus, together with previous results, these experiments completed the characterization of how estradiol action at the membrane leads to the augmentation of neuroprogesterone synthesis through increasing cAMP, activation of protein kinase A, and the phosphorylation of TSPO and StAR in hypothalamic astrocytes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diethyl ether
Sigma-Aldrich
Methanol, low water for titration
Sigma-Aldrich
Diethyl ether, puriss., contains ~5 mg/L 2,6-di-tert.-butyl-4-methylphenol as stabilizer, meets analytical specification of Ph. Eur., BP, ≥99.5% (GC)
Progesterone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Progesterone, Vetec, reagent grade, 98%
Sigma-Aldrich
Methanol, LR, ≥99%
Sigma-Aldrich
Methanol, anhydrous, ≥99.5%
Sigma-Aldrich
Diethyl ether, anhydrous, contains 5 ppm BHT as stabilizer, ≥99.5%
Sigma-Aldrich
Diethyl ether, AR, contains 5 ppm BHT as stabilizer, ≥99.5%
Sigma-Aldrich
Diethyl ether, LR, contains 5 ppm BHT as stabilizer, ≥99.5%
Sigma-Aldrich
Methanol, suitable for HPLC, ≥99.9%
Supelco
Diethyl ether, suitable for HPLC, contains 5 ppm BHT as stabilizer, ≥99%
Sigma-Aldrich
Methanol, HPLC Plus, ≥99.9%, poly-coated bottles
Sigma-Aldrich
Methanol, AR, ≥99.5%
Sigma-Aldrich
Methanol, suitable for HPLC, gradient grade, suitable as ACS-grade LC reagent, ≥99.9%
Supelco
Methanol solution, contains 0.10 % (v/v) formic acid, UHPLC, suitable for mass spectrometry (MS), ≥99.5%
Sigma-Aldrich
Dimethyl sulfoxide, LR, ≥99%
Sigma-Aldrich
Dimethyl sulfoxide, AR, ≥99.5%
Sigma-Aldrich
Dimethyl sulfoxide, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
NB001, ≥98% (HPLC)
Sigma-Aldrich
Diethyl ether, contains 1 ppm BHT as inhibitor, anhydrous, ≥99.7%
Sigma-Aldrich
Diethyl ether, suitable for HPLC, ≥99.9%, inhibitor-free
Sigma-Aldrich
Diethyl ether, ACS reagent, anhydrous, ≥99.0%, contains BHT as inhibitor